Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
Rhea-AI Summary
Nuvectis Pharma (NASDAQ: NVCT) reported second quarter 2026 results and major pipeline and financing updates. The company completed in-licensing of ex-China rights to two Haisco compounds, ciprocopan (NXP100), a once-daily oral Complement Factor B inhibitor, and NXP200, a brain-penetrant paradox-breaker BRAF inhibitor, positioning Nuvectis as a late-stage clinical development organization.
Haisco obtained July 2026 marketing approval in China for ciprocopan in PNH patients not previously treated with complement inhibitors, with a second PNH indication under review. Nuvectis plans a pre-IND FDA meeting and IND submission for ciprocopan and an IND for NXP200 in 4Q 2026. A $115 million follow-on offering in July 2026, anchored by healthcare investors, is expected to extend the cash runway into 1H 2029. Q2 2026 net loss was $7.0 million on R&D expenses of $4.7 million and G&A of $2.5 million, with June 30, 2026 cash of $22.2 million before the offering.
Positive
- $115M follow-on offering completed July 2026, extends cash runway into 1H 2029
- In-licensed ex-China rights to NXP100 and NXP200 from Haisco
- Ciprocopan received first China marketing approval for PNH not previously treated with complement inhibitors
- Q2 2026 R&D spending up to $4.7M from $3.6M, reflecting increased development activity
- Q2 2026 G&A expenses down to $2.5M from $3.0M, mainly lower public company costs
- Balance sheet shows $22.2M cash and modest total liabilities of $13.3M at June 30, 2026
Negative
- Q2 2026 net loss increased to $7.0M from $6.3M year over year
- Six-month 2026 net loss widened to $13.1M versus $11.7M in 2025
- Accumulated deficit rose to $112.8M at June 30, 2026
- Q2 2026 R&D expenses increased by $1.1M, driven by higher manufacturing, clinical, and personnel costs
- Cash and equivalents declined to $22.2M from $31.6M since December 31, 2025, prior to the July offering
News Explained
NXP900 work is narrowing to combination studies, with one ongoing and another planned; the offering’s effect on ownership remains undisclosed.
The completed July follow-on offering raised
NXP900 development is now focused on combination opportunities: one osimertinib trial is ongoing, while a lorlatinib combination study is expected to begin in the
Market reaction after 2Q26 earnings report: NVCT -6.02%
Following this news, NVCT has declined 6.02%, reflecting a notable negative market reaction. Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $20.30.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Q1 2026 earnings | Positive | +9.2% | Q1 results included clinical progress and a preliminary data readout expected in summer. |
| Feb 11 | FY 2025 earnings | Neutral | +0.5% | Year-end cash increased while annual net loss expanded and pipeline studies continued. |
| Nov 04 | Q3 2025 earnings | Negative | -7.5% | Quarterly loss increased despite Phase 1b initiation and clinical development progress. |
| Nov 04 | Q3 2025 earnings | Negative | -7.5% | Higher clinical costs and milestone expense accompanied continued NXP900 development. |
| Aug 05 | Q2 2025 earnings | Negative | -5.3% | Quarterly loss increased while R&D spending rose and Phase 1b preparation advanced. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-specific reactions were mixed, with positive and negative moves following releases that combined operating progress with ongoing losses.
Key Terms
complement factor b inhibitor medical
paroxysmal nocturnal hemoglobinuria medical
phase 1b medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development organization.
- The Company’s lead drug candidate, Ciprocopan (NXP100), a Complement Factor B inhibitor for once-daily, oral administration, was approved in China in July 2026 for the treatment of patients with PNH Previously Untreated with Complement Inhibitors.
- Completed follow-on offering in July 2026, raising
$115M in gross proceeds. Transaction anchored by leading healthcare dedicated investors and extends cash runway into 1H 2029.
FORT LEE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today reported its financial results for the second quarter of 2026 and provided an update on recent business progress.
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “The past several weeks mark a defining chapter for Nuvectis with the in-licensing of our new lead drug candidate, ciprocopan (NXP100), a Complement Factor B Inhibitor for once-daily oral administration, and the expansion of our oncology pipeline with the in-licensing of NXP200, an oral, brain-penetrant, paradox-breaker BRAF inhibitor. Approximately two weeks ago, ciprocopan received its first marketing approval in China for the treatment of patients with paroxysmal nocturnal hemoglobinuria (“PNH”) not previously treated with complement inhibitors. This approval marks the first global approval of a once-daily, oral Complement Factor B inhibitor, bringing about a meaningful new treatment option for patients with PNH in China, and also highlights ciprocopan’s compelling clinical profile and provides further validation of its therapeutic potential as a treatment for a variety of complement-mediated diseases. We congratulate our partner Haisco on this significant achievement and are excited about the opportunity to follow suit in the United States and in the other licensed territories.”
Mr. Bentsur concluded, “As expected following an in-licensing transaction that involves a late-stage asset with a multi-billion-dollar market potential, our main focus now is to advance ciprocopan toward a marketing application in the United States and other key territories, with NXP200 and NXP900 driving potential longer-term upside in the oncology segment. The successful
Recent Developments
- Completed public offering in July 2026 for gross proceeds of
$115 million , which includes the exercise of the underwriters’ overallotment. Transaction was anchored by leading healthcare investors and extends our cash runway into 1H 2029. - Ciprocopan (NXP100)
- In July 2026, our partner Haisco announced marketing approval of ciprocopan in China for the treatment of patients with PNH previously untreated with complement inhibitors. The marketing application in China for the treatment of PNH patients previously treated with anti C5 therapy is under review.
- U.S. regulatory efforts underway; a pre-investigation new drug (“IND”) meeting with the Food and Drug Administration (“FDA”) followed by IND submission expected in 4Q2026.
- NXP200
- Phase 1b in China in patients with BRAF-mutated solid tumors is ongoing.
- Oral presentation of additional clinical data generated by Haisco will be presented at the upcoming European Society for Medical Oncology (ESMO) conference (Madrid, Spain, October 23–27, 2026).
- U.S. regulatory efforts underway; IND submission expected in 4Q2026.
- NXP900
- With the shift in corporate focus towards the development of ciprocopan, the NXP900 clinical development will now continue with the promising, higher potential impact, combination opportunities:
- Non-small cell lung cancer (NSCLC): the clinical trial evaluating the combination of NXP900 plus osimertinib (Tagrisso™) in patients with NSCLC EGFR+ who initially responded to, and later progressed on, osimertinib, is ongoing, and we expect to provide an update by the end of this year. The initiation of the combination study of NXP900 with lorlatinib (Lorbrena®) in patients with NSCLC ALK+ who initially responded to, and later progressed on, an ALK inhibitor, is expected in 3Q2026.
- Pancreatic cancer: Based on in-bound interest from two leading medical centers in the U.S., an investigator-sponsored trial (IST) is planned to evaluate the combination of NXP900 plus daraxonrasib in patients with pancreatic cancer at these centers. Study initiation is contingent on FDA approval and availability of daraxonrasib.
- With the shift in corporate focus towards the development of ciprocopan, the NXP900 clinical development will now continue with the promising, higher potential impact, combination opportunities:
Second Quarter 2026 Financial Results
Cash, and cash equivalents were
The Company's net loss was
Research and development expenses were
General and administrative expenses were
Finance income was
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.
The company’s lead drug candidate is ciprocopan, a Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors. In PNH and other complement-mediated diseases, ciprocopan is expected to provide a meaningful convenience advantage as a once-daily, oral treatment option for diseases requiring lifelong treatment.
NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, including central nervous system cancer, colorectal cancer, melanoma, and non-small cell lung cancer, with best-in-class potential.
NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases, including SRC and YES1 intended to inhibit the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the SRC signaling pathway.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate", "believe", "contemplate", "could", "estimate", "expect", "intend", "seek", "may", "might", "plan", "potential", "predict", "project", "target", "aim", "should", "will", "would", or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the use of proceeds from the public offering and the approvability and market potential of our pipeline products. Forward looking statements are based on Nuvectis’ current expectations, estimates, and projections and past interpretations of data and information available, including preclinical and clinical safety, pharmacokinetics, pharmacodynamics, and efficacy data generated to date for its pipeline products NXP100, NXP200, and NXP900, and estimates and projections regarding Nuvectis’ financial condition. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions and described more fully in the section titled "Risk Factors" in Nuvectis’ second quarter 2026 Form 10-Q and Nuvectis’ other public filings with the U.S. Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Nuvectis’ expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
| NUVECTIS PHARMA, INC. BALANCE SHEET (USD in thousands, except per share and share amounts) | |||||||
| June 30, | December 31, | ||||||
| 2026 | 2025 | ||||||
| Assets | |||||||
| CURRENT ASSETS | |||||||
| Cash and cash equivalents | $ | 22,160 | $ | 31,634 | |||
| Other current assets | 216 | 75 | |||||
| TOTAL CURRENT ASSETS | 22,376 | 31,709 | |||||
| TOTAL ASSETS | $ | 22,376 | $ | 31,709 | |||
| Liabilities and Shareholders’ Equity | |||||||
| CURRENT LIABILITIES | |||||||
| Accounts payable | $ | 5,184 | $ | 6,274 | |||
| Deferred fundraising receipts | 1,388 | — | |||||
| Accrued liabilities | 92 | 115 | |||||
| Employee compensation and benefits | 6,630 | 6,907 | |||||
| TOTAL CURRENT LIABILITIES | 13,294 | 13,296 | |||||
| TOTAL LIABILITIES | 13,294 | 13,296 | |||||
| COMMITMENTS AND CONTINGENCIES | |||||||
| SHAREHOLDERS’ EQUITY | |||||||
| Common Shares, | * | * | |||||
| Additional paid in capital | 121,839 | 118,100 | |||||
| Accumulated deficit | (112,757 | ) | (99,687 | ) | |||
| TOTAL SHAREHOLDERS’ EQUITY | 9,082 | 18,413 | |||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 22,376 | $ | 31,709 | |||
* Represents an amount lower than
| NUVECTIS PHARMA, INC. STATEMENT OF OPERATIONS (USD in thousands, except per share and share amounts) | |||||||||||||||
| Three Months Ended June 30 | Six Months Ended June 30 | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| OPERATING EXPENSES | |||||||||||||||
| Research and development | $ | 4,684 | $ | 3,613 | $ | 8,790 | $ | 7,293 | |||||||
| General and administrative | 2,513 | 2,982 | 4,667 | 4,870 | |||||||||||
| OPERATING LOSS | (7,197 | ) | (6,595 | ) | (13,457 | ) | (12,163 | ) | |||||||
| Finance income | 177 | 261 | 387 | 497 | |||||||||||
| NET LOSS | $ | (7,020 | ) | $ | (6,334 | ) | $ | (13,070 | ) | $ | (11,666 | ) | |||
| TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | $ | (7,020 | ) | $ | (6,334 | ) | $ | (13,070 | ) | $ | (11,666 | ) | |||
| BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING | $ | (0.30 | ) | $ | (0.30 | ) | $ | (0.56 | ) | $ | (0.56 | ) | |||
| Basic and diluted weighted average number of common shares outstanding | 23,475,989 | 21,366,268 | 23,445,397 | 20,655,856 | |||||||||||
